Advanced Search

Home > Journals > Acta Phlebologica > Past Issues > Acta Phlebologica 2013 December;14(3) > Acta Phlebologica 2013 December;14(3):115-21

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEACTA PHLEBOLOGICA

A Journal on Phlebology

Official Journal of the Italian College of Phlebology
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index

Frequency: 3 issues

ISSN 1593-232X

Online ISSN 1827-1766

 

Acta Phlebologica 2013 December;14(3):115-21

    ORIGINAL ARTICLES

Pulmonary embolism, metalloproteinases and neutrophil gelatinase associated lipocalin

Busceti M. T. 1, Grande R. 1, Amato B. 2, 3, Gasbarro V. 3, 4, Buffone G. 1, Amato M. 2, Gallelli L. 3, Serra R. 1, 3, De Franciscis S. 1, 3

1 Department of Medical and Surgical Science Magna Graecia University, Catanzaro, Italy;
2 Department of Clinical Medicine Federico II University, Naples, Italy;
3 Interuniversity Center of Phlebolymphology International Research and Educational Program in Clinical and Experimental Biotechnology Magna Graecia University, Catanzaro, Italy;
4 Department of Vascular Surgery Ferrara University, Ferrara, Italy

Aim: Pulmonary embolism (PE) is a common disease related to significant morbidity and mortality. Several prognostic models have been developed to assess the risk of complications in patients with PE. Metalloproteinases (MMPs) seem to be involved in both respiratory and endothelial dysfunction in PE. In this study we evaluated plasma levels of MMP-2, MMP-9 and Neutrophil Gelatinase Associated Lipocalin (NGAL) in patients with PE.
Methods: An open label, parallel groups study in three clinical departments was conducted between January 2010-December 2012. Patients eligible for the study were of both sexes, from 20 up to 70 years, with a diagnosis of PE. ELISA testing was used to determine the concentration of MMP-2, MMP-9, NGAL in plasma of enrolled patients.
Results: Seventeen patients with PE (14M, 3F) were enrolled. Patients were divided in two groups according to Pulmonary Embolism Severity Index (PESI): Group I (high risk); Group II (low risk); Group III (healthy volunteers, as control group). ELISA findings revealed significantly higher levels (P<0.01) of MMP-2, MMP-9 and NGAL in plasma of PE patients (Group I and II) respect to control patients (Group III) and the levels of MMP-9 and NGAL were also significantly higher in patients at high risk (P<0.01) (Group I).
Conclusion: This study showed a role of the dosage of plasmatic MMPs and NGAL in order to better classify the prognosis of patients with PE.

language: English


FULL TEXT  REPRINTS

top of page